| Name | 2-[4,6-bis(dimethylamino)-2-[[4-[[4-(trifluoromethyl)benzoyl]amino]phenyl]methyl]pyrimidin-5-yl]acetic acid |
|---|---|
| Synonyms |
UNII-721F767LHB
Actimis BI-671800 |
| Description | BI-671800 is a highly specific and potent antagonist of chemoattractant receptor-homologous molecule on Th2 cells (DP2/CRTH2), with IC50 values of 4.5 nM and 3.7 nM for PGD2 binding to CRTH2 in hCRTH2 and mCRTH2 transfected cells, respectively[1]. BI-671800 has potential for the treatment of poorly controlled asthma[2]. |
|---|---|
| Related Catalog | |
| Target |
hCRTH2:4.5 nM (IC50, in CRTH2 transfected cells) mCRTH2:3.7 nM (IC50, in CRTH2 transfected cells) |
| In Vitro | BI-671800 (compound A) exhibits low nM potency as an antagonist of human or mouse CRTH2 in transfected cells[1]. |
| In Vivo | BI-671800 (compound A, 0.1-10 mg/kg, i.g.) shows significant inhibition of AHR in mice[1]. BI-671800 (compound A), effectively blocks edema formation and greatly reduces the inflammatory infiltrate and skin pathology observed in drug vehicle-treated animals[3]. |
| References |
| Molecular Formula | C25H26F3N5O3 |
|---|---|
| Molecular Weight | 501.50100 |
| Exact Mass | 501.19900 |
| PSA | 102.15000 |
| LogP | 4.48160 |
| Storage condition | 2-8℃ |